| Dr Amber Ann Wallace, MD | |
|
1686 Skylyn Dr, Suite 101, Spartanburg, SC 29307 | |
| (864) 560-3456 | |
| Not Available |
| Full Name | Dr Amber Ann Wallace |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 19 Years |
| Location | 1686 Skylyn Dr, Spartanburg, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104035526 | NPI | - | NPPES |
| SC07926162 | Other | SC | MEDICARE PIN |
| P01330093 | Other | SC | RAILROAD MEDICARE |
| NC1735 | Medicaid | SC | |
| SC07923365 | Other | SC | MEDICARE PIN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Spartanburg Medical Center | Spartanburg, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spartanburg Medical Center | 3072425297 | 843 |
News Archive
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Two years and more than 2,000 samples after researchers at Baylor College of Medicine started to use a new gene-chip technology called chromosomal microarray analysis to look for potential genetic abnormalities in children, they find that it is remarkably sensitive in detecting abnormalities in individual chromosomes, according to a report that appears online today in the journal Public Library of Science ONE.
A four-year study on iron metabolism within cells, an essential process that impacts both iron deficiency and iron toxicity, conditions responsible for a multitude of human diseases, is underway at the University at Buffalo funded by a $1.16 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
› Verified 3 days ago
| Entity Name | Spartanburg Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043309917 PECOS PAC ID: 3072425297 Enrollment ID: O20031105000129 |
News Archive
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Two years and more than 2,000 samples after researchers at Baylor College of Medicine started to use a new gene-chip technology called chromosomal microarray analysis to look for potential genetic abnormalities in children, they find that it is remarkably sensitive in detecting abnormalities in individual chromosomes, according to a report that appears online today in the journal Public Library of Science ONE.
A four-year study on iron metabolism within cells, an essential process that impacts both iron deficiency and iron toxicity, conditions responsible for a multitude of human diseases, is underway at the University at Buffalo funded by a $1.16 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
› Verified 3 days ago
| Entity Name | Spartanburg Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760114664 PECOS PAC ID: 3072425297 Enrollment ID: O20040108000827 |
News Archive
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Two years and more than 2,000 samples after researchers at Baylor College of Medicine started to use a new gene-chip technology called chromosomal microarray analysis to look for potential genetic abnormalities in children, they find that it is remarkably sensitive in detecting abnormalities in individual chromosomes, according to a report that appears online today in the journal Public Library of Science ONE.
A four-year study on iron metabolism within cells, an essential process that impacts both iron deficiency and iron toxicity, conditions responsible for a multitude of human diseases, is underway at the University at Buffalo funded by a $1.16 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
› Verified 3 days ago
| Entity Name | Scotland Memorial Hospital, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770577611 PECOS PAC ID: 0648208504 Enrollment ID: O20080304000638 |
News Archive
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Two years and more than 2,000 samples after researchers at Baylor College of Medicine started to use a new gene-chip technology called chromosomal microarray analysis to look for potential genetic abnormalities in children, they find that it is remarkably sensitive in detecting abnormalities in individual chromosomes, according to a report that appears online today in the journal Public Library of Science ONE.
A four-year study on iron metabolism within cells, an essential process that impacts both iron deficiency and iron toxicity, conditions responsible for a multitude of human diseases, is underway at the University at Buffalo funded by a $1.16 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amber Ann Wallace, MD Po Box 743070, Atlanta, GA 30374-3070 Ph: (864) 560-4304 | Dr Amber Ann Wallace, MD 1686 Skylyn Dr, Suite 101, Spartanburg, SC 29307 Ph: (864) 560-3456 |
News Archive
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Two years and more than 2,000 samples after researchers at Baylor College of Medicine started to use a new gene-chip technology called chromosomal microarray analysis to look for potential genetic abnormalities in children, they find that it is remarkably sensitive in detecting abnormalities in individual chromosomes, according to a report that appears online today in the journal Public Library of Science ONE.
A four-year study on iron metabolism within cells, an essential process that impacts both iron deficiency and iron toxicity, conditions responsible for a multitude of human diseases, is underway at the University at Buffalo funded by a $1.16 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
› Verified 3 days ago
Kristine Dee Boyd, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 853 N Church St Ste 700, Spartanburg, SC 29303 Phone: 864-560-6164 Fax: 864-560-7092 | |
Dr. Grantham Dewitt Warren, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 853 N Church St, Suite 600, Spartanburg, SC 29303 Phone: 864-583-4556 Fax: 864-560-0625 | |
Dr. Hugh W Barrow Jr., M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 853 N Church St, Suite 600, Spartanburg, SC 29303 Phone: 864-583-4556 Fax: 864-560-0625 | |
Ashley Beasley Benson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 475 Heywood Ave, Spartanburg, SC 29307 Phone: 864-699-5020 Fax: 864-699-5050 | |
Dr. Peter Arnold Sereque, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 250 N Grove Medical Park Dr, Spartanburg, SC 29303 Phone: 864-560-7002 Fax: 864-560-6009 | |
Kimberly F Toler, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1686 Skylyn Drive, Suite 101, Spartanburg, SC 29307 Phone: 864-585-3456 |